Biosimilars 101

Slide 1

Biosimilars 101

Biosimilars work just as well as the drugs they’re modeled after — and they’re often more affordable. This quick guide will help you understand whether biosimilars could be an option for you.

Slide 2

What are biosimilars?

Biosimilars are copies of a type of drug called biologics . Biologics are drugs made from a natural source, such as plant or human cells. Biologics and biosimilars are used to treat a variety of health problems, including:

Rheumatoid arthritis (RA)

Psoriasis

Crohn’s disease

Various types of cancer

Slide 3

Biosimilars are safe and effective

Biosimilars are nearly identical to biologics, working in the same way to treat many of the same health problems. They are safe, effective and FDA-approved.

Slide 4

Lower production costs = cheaper drugs

Because they’re much cheaper to produce, biosimilars are more affordable than biologics — which are among the most expensive medications in the world. Biologics used to treat RA, for example, can cost $30,000 a year .

Slide 5

Picking possible candidates

Companies decide to create biosimilars based on factors such as how much they will cost and whether they have a good chance of working the same way as a biologic.

Slide 6

Meeting FDA standards

Once they’ve decided to create a biosimilar, a company analyzes and compares data to develop a drug that meets the FDA’s high standards. The biosimilar is tested many times to prove it works in the exact same way as the original biologic.

Slide 7

Availability of biosimilars

Currently, there are 44 biosimilars approved by the FDA for use in the United States.

These include 10 biosimilars modeled after a dalimumab (Humira), a medicine used to treat autoimmune issues.

Slide 8

Roadblocks to biosimilars

Although demand for biosimilars is growing in the U.S., they’re still not as widely used here as they are in other countries.

This may be because some biologic manufacturers have tried to block their development, and because some insurance companies aren’t willing to cover them.

Slide 9

Helping people access treatment

Biosimilars are important to our healthcare system because they provide a more affordable option for patients who might not otherwise be able to access treatment.

Biosimilars are 30% cheaper on average than their biologic counterparts.

Slide 10

Are biosimilars right for you?

If you are currently using a biologic, ask your healthcare provider about biosimilars. It’s possible there is an equally safe and effective option available to you, at a lower cost.

This educational resource was created with support from Amgen, a HealthyWomen Corporate Advisory Council member.